Prostatype Genomics AB (PROGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Prostatype Genomics AB (PROGEN) has a cash flow conversion efficiency ratio of -0.234x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-8.54 Million ≈ $-918.99K USD) by net assets (Skr36.48 Million ≈ $3.93 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See PROGEN equity to assets ratio to measure how much of total assets are equity-financed.
Prostatype Genomics AB - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Prostatype Genomics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how aggressively does Prostatype Genomics AB reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Prostatype Genomics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Prostatype Genomics AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Tongyang Inc
KO:001527
|
-0.008x |
|
GOLDREA RES CORP.
F:GOJ1
|
N/A |
|
VCI Global Limited Ordinary Share
NASDAQ:VCIG
|
0.154x |
|
GENERAL COPPER GOLD CORP.
F:7S50
|
0.007x |
|
McLaren Resources Inc
F:3ML
|
0.398x |
|
NANOSPHERE
F:3NS
|
-0.003x |
|
Enersize Oy
ST:ENERS
|
0.057x |
|
Starbox Group Holdings Ltd. Ordinary Shares
NASDAQ:STBX
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Prostatype Genomics AB (2016–2024)
The table below shows the annual cash flow conversion efficiency of Prostatype Genomics AB from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see market value of Prostatype Genomics AB.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr33.47 Million ≈ $3.60 Million |
Skr-44.71 Million ≈ $-4.81 Million |
-1.336x | -13.12% |
| 2023-12-31 | Skr24.67 Million ≈ $2.66 Million |
Skr-29.14 Million ≈ $-3.14 Million |
-1.181x | -11.52% |
| 2022-12-31 | Skr26.15 Million ≈ $2.81 Million |
Skr-27.69 Million ≈ $-2.98 Million |
-1.059x | -136.49% |
| 2021-12-31 | Skr35.91 Million ≈ $3.86 Million |
Skr-16.08 Million ≈ $-1.73 Million |
-0.448x | +13.89% |
| 2020-12-31 | Skr28.29 Million ≈ $3.04 Million |
Skr-14.71 Million ≈ $-1.58 Million |
-0.520x | +53.85% |
| 2018-12-31 | Skr8.55 Million ≈ $919.74K |
Skr-9.63 Million ≈ $-1.04 Million |
-1.127x | -22.82% |
| 2017-12-31 | Skr6.22 Million ≈ $669.69K |
Skr-5.71 Million ≈ $-614.46K |
-0.918x | -42.21% |
| 2016-12-31 | Skr14.93 Million ≈ $1.61 Million |
Skr-9.63 Million ≈ $-1.04 Million |
-0.645x | -- |
About Prostatype Genomics AB
Prostatype Genomics AB (publ) manufactures, markets, and sells prognostic gene tests. The company offers Prostatype Test System that combines gene expression information with used clinical parameters, such as PSA, gleason score, and tumor stage, as well as calculates the P-score. Its test is based on database containing prostate cancer patients; and provides decision support for patients and doct… Read more